Showing results (311-320 of 649) with videos related to
Sort By:
Pageof 65
Hemasphere|December 13, 2021
Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus ProposalPeter Valent, Cem Akin, Karin Hartmann, et al.Hemasphere|December 29, 2021
Hfe Is Highly Expressed in Liver Sinusoidal Endothelial Cells But Is Not Needed to Maintain Systemic Iron Homeostasis In VivoSilvia Colucci, Katja Müdder, Martina U Muckenthaler, et al.Hemasphere|December 29, 2021
Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working PartyJesse M Tettero, Sylvie Freeman, Veit Buecklein, et al.Hemasphere|February 10, 2022
What Prognostic Markers Should Be Evaluated in Marginal Zone Lymphoma? A Survey Among Leading International ExpertsCôme Bommier, Jérôme Lambert, Grzegorz Nowakowski, et al.Hemasphere|April 15, 2022
Outcome of COVID-19 in Patients With Mantle Cell Lymphoma-Report From the European MCL RegistryMarie-Kristin Tilch, Carlo Visco, Sandra Kinda, et al.Hemasphere|January 31, 2022
The EHA Research Roadmap: Transfusion MedicineSimon J Stanworth, Anneke Brand, Srini V Kaveri, et al.Hemasphere|October 15, 2021
Management and Outcomes of Diffuse Large B-cell Lymphoma Post-transplant Lymphoproliferative Disorder in the Era of PET and Rituximab: A Multicenter Study From the Australasian Lymphoma AllianceStephen Boyle, Joshua W D Tobin, Jacinta Perram, et al.Hemasphere|April 8, 2022
Prognostic Stratification of Diffuse Large B-cell Lymphoma Using Clinico-genomic Models: Validation and Improvement of the LymForest-25 ModelAdrián Mosquera Orgueira, Jose Ángel Díaz Arías, Miguel Cid López, et al.Hemasphere|March 2, 2022
Immunochemotherapy and Maintenance With Obinutuzumab or Rituximab in Patients With Previously Untreated Marginal Zone Lymphoma in the Randomized GALLIUM TrialMichael Herold, Eva Hoster, Ann Janssens, et al.Pageof 65